Table 3

Lack of emergence of drug resistance mutations in six patients treated with up to 2 years of triple therapy and undetectable plasma RNA. In five of six patients, substitutions in position 63 of the protease corresponding to known natural polymorphisms (24) were seen at baseline and in virus isolates. In patient K, a natural polymorphism was found in position 71 at baseline and after 2 years. Box denotes data indicating a residue where the sequence after 2 years of treatment was wild type in one culture despite a resistance mutation at baseline. (–) indicates identity with consensus clade B sequence. Abbreviations for amino acids: A, Ala; D, Asp; I, Ile; K, Lys; L, Leu; M, Met; N, Asn; P, Pro; Q, Gln; R, Arg; T, Thr; V, Val; and Y, Tyr.

PatientWeeks on treatmentSampleAmino acid residue associated with resistance and Clade B reference sequence
Protease geneReverse transcriptase gene
10 L20 K24 L32 V46 M54 I63 L71 A82 V84 I90 L41 M67 D70 K184 M215 T219 K
A0PlasmaPR
104CulturePR
B0PlasmaPR
92Culture 1P
100Culture 2PR
92Passage 1P
C0PlasmaPNRQ
96CulturePNRQ
K0PlasmaTVLY
100CultureTVLY
L0PlasmaPNQ
96CulturePNQ
M0PlasmaLNRY
100CultureLNRY